Roche reported negative results Monday from a pair of clinical trials investigating an antibody treatment for people with early-stage Alzheimer’s disease — another setback for the Swiss pharma giant’s decades-long effort to develop medicines against the memory-destroying disease.
The drug, called gantenerumab, slowed the rate of cognitive and functional decline compared to a placebo by 8% and 6%, respectively, — not enough to meet the primary goal of the two studies of just under 2,000 patients with early-stage Alzheimer’s, Roche said in a press release.
Click this link for the original source of this article.
Author: Adam Feuerstein and Damian Garde
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.